Evidence map›Paper›PMID 42357807›Full record

SynthesisEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2026

Early catheter ablation vs. antiarrhythmic drugs in treatment-naïve ischaemic ventricular tachyarrhythmias: a meta-analysis of randomized controlled trials.

Tiago Moura Façanha, Anna Isabelle Gomes Pereira, Maria Fernanda Carvalho Garcia, Enzo Tunala Mendonça, João Vitor Jacobsen Ramos, Leonardo Antunes Mesquita

Abstract readMeta-AnalysisReviewComparative Study
In one paragraph

Synthesis in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. How early should we ablate ventricular tachycardia? From rescue to prevention in ischaemic VT.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tiago Moura FaçanhaFaculty of Medicine, University of Fortaleza, Fortaleza, Ce, Brazil.ORCID 0009-0006-3716-6153
Anna Isabelle Gomes PereiraFaculty of Medicine, FAMETRO University Center, Manaus, AM, Brazil.ORCID 0009-0003-3558-144X
Maria Fernanda Carvalho GarciaFaculty of Medical and Health Sciences, SUPREMA, Juiz de Fora, Brazil.ORCID 0009-0000-3973-3269
Enzo Tunala MendonçaFaculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.ORCID 0009-0003-1935-0924
João Vitor Jacobsen RamosFaculty of Medicine, Santa Casa de Misericórdia de Vitória, Vitória, ES, Brazil.ORCID 0009-0005-7550-5657
Leonardo Antunes MesquitaDepartment of Electrophysiology, Hospital Madre Teresa, Avenida Raja Gabaglia 1002, Gutierrez, Belo Horizonte, MG 30441-070, Brazil.ORCID 0009-0007-9122-0904

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAntiarrhythmic drugs (AADs) have traditionally been used as first-line therapy for ventricular tachycardia (VT) but are frequently associated with systemic toxicities and drug interactions. Therefore, we performed a meta-analysis comparing early catheter ablation (CA) with AAD therapy as initial treatment for VT in patients with prior myocardial infarction. METHODS AND

resultsPubMed, Embase, and the Cochrane Library were searched for randomized controlled trials comparing CA vs. AAD in patients naïve to both strategies. Meta-analysis was performed using Review Manager. Three randomized trials including 618 patients were analysed. No significant differences were observed in all-cause mortality, appropriate implantable cardioverter-defibrillator (ICD) therapies (including shocks and antitachycardia pacing), ventricular arrhythmia storm, hospitalizations, or adverse events between strategies. Leave-one-out sensitivity analysis identified one trial as the primary contributor to between-study heterogeneity.

conclusionEarly catheter ablation provides similar efficacy to first-line antiarrhythmic drug therapy for major arrhythmic and survival outcomes, with reductions in hospitalizations and treatment-related adverse events, although largely driven by one trial. These findings support consideration of CA as a first-line therapeutic strategy in selected patients with ischaemic VT.

Indexed as

Anti-Arrhythmia AgentsCatheter AblationMyocardial IschemiaTachycardia, VentricularHumansRandomized Controlled Trials as TopicRisk FactorsTime FactorsTreatment OutcomeAnti-Arrhythmia AgentsCatheter ablationDrug-naïveDrug therapyFirst-line therapyTreatment-naïveVentricular tachyarrhythmias

Identifiers

PMID42357807
PMCPMC13303077

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.